Eczema - dyshidrotic
Methodology & AI Transparency ⓘ
Eczema - dyshidrotic Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Diagnostic registry L30.8: Eczema - dyshidrotic is managed within Skin & Dermatology.
- 3 Typical cash cost range: Clinicians assessing Eczema - dyshidrotic focus on cutaneous immune skewing in Eczema - dyshidrotic (L30.8: (Th2/IL-4/IL-13 in atopic) and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Eczema - dyshidrotic: maintaining 25-Hydroxy Vitamin D in Eczema - dyshidrotic (L30.8: & hs-CRP) within 25(OH)D 40–65 ng/mL (L30.8).
Ask our AI Specialists anything about Eczema - dyshidrotic
What Is Eczema - dyshidrotic?
Recognized across U.S. clinical coding as L30.8 (Skin & Dermatology), Eczema - dyshidrotic is evaluated via dermoscopy or punch in Eczema - dyshidrotic (L30.8: biopsy when atypical) to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Eczema - dyshidrotic (L30.8) features cutaneous immune skewing in Eczema - dyshidrotic (L30.8: (Th2/IL-4/IL-13 in atopic). therapeutic stabilization in skin & dermatology is verified against Affected Body Surface in Eczema - dyshidrotic (L30.8: Area (BSA /).
Common Symptoms & Clinical Signs
- • Presentation of Eczema - dyshidrotic (L30.8): compromised epidermal barrier in Eczema - dyshidrotic (L30.8: with dryness, fissuring,)
- • Secondary Eczema - dyshidrotic clinical sign: post-inflammatory hyperpigmentation, facial in Eczema - dyshidrotic (L30.8: flushing, or pitted)
- • Symptom flares in Eczema - dyshidrotic correlating with 25-Hydroxy Vitamin D in Eczema - dyshidrotic (L30.8: & hs-CRP) deviation outside 25(OH)D 40–65 ng/mL (L30.8)
- • Functional skin & dermatology impact requiring dermoscopy or punch in Eczema - dyshidrotic (L30.8: biopsy when atypical) evaluation (L30.8)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Eczema - dyshidrotic Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L30.8 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Eczema - dyshidrotic (L30.8: & hs-CRP) | 25(OH)D 40–65 ng/mL (L30.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Eczema - dyshidrotic (L30.8: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L30.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Eczema - dyshidrotic (L30.8: ALT (if systemic) | Within baseline reference limits (L30.8) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Eczema - dyshidrotic
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Roycederm Eczema Relief Cream (Colloidal Oatmeal 1%) Roycederm Eczema Relief Cream • RxCUI 240651-B85424010 | Non-Standardized Food Allergenic Extract | 92% | $0.9000 | $ 73.30 /mo |
| Triderma Eczema Fast Healing Face Body (E Relief) Triderma Eczema Fast Healing Face Body • RxCUI 1189915 | Non-Standardized Food Allergenic Extract | 83% | $2.7700 | $ 207.94 /mo |
| Serawise Eczema Relief (Oatmeal) Serawise Eczema Relief • RxCUI 240651-B85050012 | Non-Standardized Food Allergenic Extract | 93% | $3.3100 | $ 246.82 /mo |
| Eczema (Oatmeal) Eczema • RxCUI 1437616-B52915010 | Non-Standardized Food Allergenic Extract | 83% | $0.3200 | $ 31.54 /mo |
| Eczema Itch Relief Wash and Shampo (Colloidal Oatmeal) Eczema Itch Relief Wash and Shampo • RxCUI 2396990-B10738162 | Non-Standardized Food Allergenic Extract | 88% | $2.3500 | $ 177.70 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Eczema - dyshidrotic)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Effect of Delgocitinib Cream on Health-Related Quality of Life in Patients With: What a 639-Participant Study Found Delgocitinib cream resulted in clinically significant improvement in HRQoL compared with cream vehicle. Contact dermatitis • 2026-07-15 • Phase III Randomized Trial | N = 639 | 93/100 | PMID 41775339 ↗ |
| New Insights on Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients: What a 564-Participant Study Found LEB was associated with high rates of durable absolute EASI response, even in cases of high baseline severity or suboptimal week-16 outcomes. Acta dermato-venereologica • 2026-05-21 • Phase III Randomized Trial | N = 564 | 93/100 | PMID 42163822 ↗ |
| New Insights on Dupilumab Provides Clinically Meaningful Responses in Children Aged 6-11 Years: What a 304-Participant Study Found Treatment with dupilumab provides significant and sustained improvements within 2 weeks in AD signs, symptoms, and QoL in almost all children with severe AD, including those who did not achieve clear or almost clear skin by... American journal of clinical dermatology • 2023-09-15 • Phase III Randomized Trial | N = 304 | 93/100 | PMID 37300760 ↗ |
| What the Latest Evidence Really Says About Factors associated with depression, anxiety and severe mental illness among Our review highlights limited existing research on factors associated with depression, anxiety and SMI in adults with AE or psoriasis. The British journal of dermatology • 2023-03-30 • Meta-Analysis | Multi-cohort | 92/100 | PMID 36745557 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of upadacitinib on atopic hand eczema in patients with moderate-to-severe Upadacitinib 15 mg and 30 mg single-drug treatment provided rapid and sustained improvement in atopic hand eczema compared with placebo through Week 16 in patients with moderate-to-severe AD. Journal of the European Academy of Dermatology and Venereology : JEADV • 2023-09-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37184290 ↗ |
Eczema - dyshidrotic Patient Community & “People Like Me” Threads
Filter Eczema - dyshidrotic community threads and patient logs by age, biological sex, dosage, and treatment duration.